Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS assessed both in tumor and blood sample, as a marker of response to enzalutamide in patients with metastatic castration resistant prostate cancer (CRPC) pre-chemotherapy
Data de publicación
2015Título da revista
Journal Of Clinical Oncology
Tipo de contido
Publicación de congreso